Daniel Fishman
Research Subjects
Research Interests
Daniel Fishman has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alex Braiman
Department of Microbiology, Immunology, Genetics,Ben-Gurion University of the Negev,Beersheba,Israel, Israel
1 shared publication - Anton Osyntsov
Department of General Surgery, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel
1 shared publication - Ariel Weiner
Azrieli Faculty of Medicine,Bar-Ilan University,Ramat Gan,Israel, Israel
1 shared publication - Elena Voronov
Ben-Gurion University of the Negev, Be’er Sheva, Israel
1 shared publication - Guy Barsky
Medical School for International Health, Ben-Gurion University of the Negev, Be’er Sheva 8410501, Israel
1 shared publication - Irena Kaplanov
Microbiology, Immunology and Genetics,Ben-Gurion University of the Negev,Beersheba,Israel, Israel
1 shared publication
Latest Publications
- Open Access
- 23 September 2026
- Published by MDPI AG in Preprints.org
Inhibition of IL-1β in Colon Cancer Microenvironment Declines Tumor Growth by Regulation of Anti-Tumor Immunity and Colon Microbiome
(1) Background: Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. The tumor microenvironment (TME) is a key driver of disease progression, shaping both pro- and anti-tumor immune responses. Interleukin-1β (IL-1β) is a pleiotropic pro-inflammatory cytokine that participates in both homeostatic and pathological conditions. It has been shown to be upregulated in many tumors, including CRC, where it promotes angiogenesis, immunosuppression, and resistance to chemotherapy. (2) Objective: Elucidate the correlation between TME IL-1β and colon microbiotic changes during CRC progression and approach inhibition of IL-1β as a therapeutic strategy in combination with chemotherapy. (3) Design: Using an orthotopic mouse model of CRC, we compared tumor growth, metastatic spread, immune infiltration and microbiome composition in control and IL-1β knockout mice. In addition, we studied the effects of IL-1β neutralization alone or in combination with FOLFOX chemotherapy on CRC prognosis. (4) Results: IL-1β promoted CRC progression by enhancing pro-inflammatory signalling, recruiting immunosuppressive myeloid cells, and driving microbiome dysbiosis. In contrast, IL-1β deficiency increased antigen-presenting myeloid cells and CD8+ T-cell infiltration, leading to delayed tumor growth and reduced metastasis. FOLFOX chemotherapy alone exacerbated systemic and local inflammation, facilitating liver metastasis. Strikingly, the addition of IL-1β blockade abrogated FOLFOX-induced inflammation, enhanced anti-tumor immunity, and prevented metastatic spread. (5) Conclusions: IL-1β from the TME links microbiome dysbiosis, tumor-promoting inflammation and poor chemotherapy outcomes in CRC. Combining IL-1β inhibition with standard FOLFOX chemotherapy represents a promising therapeutic approach to improve prognosis in CRC patients.
- 23 September 2026
- Published by MDPI AG in Preprints.org
Open AccessInhibition of IL-1β in Colon Cancer Microenvironment Declines Tumor Growth by Regulation of Anti-Tumor Immunity and Colon Microbiome
(1) Background: Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. The tumor microenvironment (TME) is a key driver of disease progression, shaping both pro- and anti-tumor immune responses. Interleukin-1β (IL-1β) is a pleiotropic pro-inflammatory cytokine that participates in both homeostatic and pathological conditions. It has been shown to be upregulated in many tumors, including CRC, where it promotes angiogenesis, immunosuppression, and resistance to chemotherapy. (2) Objective: Elucidate the correlation between TME IL-1β and colon microbiotic changes during CRC progression and approach inhibition of IL-1β as a therapeutic strategy in combination with chemotherapy. (3) Design: Using an orthotopic mouse model of CRC, we compared tumor growth, metastatic spread, immune infiltration and microbiome composition in control and IL-1β knockout mice. In addition, we studied the effects of IL-1β neutralization alone or in combination with FOLFOX chemotherapy on CRC prognosis. (4) Results: IL-1β promoted CRC progression by enhancing pro-inflammatory signalling, recruiting immunosuppressive myeloid cells, and driving microbiome dysbiosis. In contrast, IL-1β deficiency increased antigen-presenting myeloid cells and CD8+ T-cell infiltration, leading to delayed tumor growth and reduced metastasis. FOLFOX chemotherapy alone exacerbated systemic and local inflammation, facilitating liver metastasis. Strikingly, the addition of IL-1β blockade abrogated FOLFOX-induced inflammation, enhanced anti-tumor immunity, and prevented metastatic spread. (5) Conclusions: IL-1β from the TME links microbiome dysbiosis, tumor-promoting inflammation and poor chemotherapy outcomes in CRC. Combining IL-1β inhibition with standard FOLFOX chemotherapy represents a promising therapeutic approach to improve prognosis in CRC patients.